BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLRX BioLine Rx

Market Closed 02-14 16:00:00 EST

3.71

+0.20

+5.70%

盘后3.69

-0.02-0.54%

19:59 EST

High3.86	Low3.44	Vol110.67K
Open3.51	D1 Closing3.51	Amplitude11.97%
Mkt Cap13.80M	Tradable Cap12.54M	Total Shares3.72M
T/O401.19K	T/O Rate3.27%	Tradable Shares3.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BLRX","market":"US","secType":"STK","nameCN":"BioLine Rx","latestPrice":3.71,"timestamp":1739566800000,"preClose":3.51,"halted":0,"volume":110671,"hourTrading":{"tag":"盘后","latestPrice":3.69,"preClose":3.71,"latestTime":"19:59 EST","volume":11996,"amount":44668.474,"timestamp":1739581141475},"delay":0,"floatShares":3380655,"shares":3721003,"eps":-10.4766,"marketStatus":"Market Closed","change":0.2,"latestTime":"02-14 16:00:00 EST","open":3.51,"high":3.86,"low":3.44,"amount":401188.7607167,"amplitude":0.119658,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.4766,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":3.51,"preHourTrading":{"tag":"盘前","latestPrice":3.47,"preClose":3.51,"latestTime":"08:40 EST","volume":99,"amount":343.12091219999996,"timestamp":1739540415615},"postHourTrading":{"tag":"盘后","latestPrice":3.69,"preClose":3.71,"latestTime":"19:59 EST","volume":11996,"amount":44668.474,"timestamp":1739581141475},"volumeRatio":1.3674532479514756,"impliedVol":0.8856,"impliedVolPercentile":0.768},"requestUrl":"/m/hq/s/BLRX","defaultTab":"news","newsList":[{"id":"2511866067","title":"BioLine RX Ltd  expected to post a loss of 93 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2511866067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511866067?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:15","pubTimestamp":1739538908,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of93cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports  results on February 17 (est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nL8N3P516O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2509555288","title":"BioLine RX Ltd  expected to post a loss of 93 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2509555288","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509555288?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:46","pubTimestamp":1738759567,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of93cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports  results on February 7 (esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nL8N3OW1OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":1},{"id":"2507963327","title":"BioLine RX Ltd  expected to post a loss of 93 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2507963327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507963327?lang=en_us&edition=fundamental","pubTime":"2025-01-31 22:05","pubTimestamp":1738332308,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of93cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports  results on February 4 (esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL5N3OR1HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2507936066","title":"BioLineRx trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2507936066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507936066?lang=en_us&edition=fundamental","pubTime":"2025-01-30 08:50","pubTimestamp":1738198208,"startTime":"0","endTime":"0","summary":"19:50 EST BioLineRx (BLRX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLRX","BK4139"],"gpt_icon":0},{"id":"2505221198","title":"BioLineRx Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2505221198","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505221198?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"- Company outlines strategic long-term vision and financial outlook -. TEL AVIV, Israel, Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders.It has been approximately two months since we announced a major strategy shift with the signing of an exclusive license agreement with Ayrmid Ltd. to commercialize APHEXDA, the next-generation stem cell mobilization agent that we successfully shepherded from early clinical development through FDA approval and commercial launch in September 2023. Following such a transformational transaction, I wanted to provide more granularity regarding our vision for our company moving forward, as we remain as committed as ever to maximizing value for our shareholders.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-issues-letter-shareholders-120000456.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biolinerx-issues-letter-shareholders-120000456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD",".IXIC","MNQmain","QID","SQQQ","BK4135","NVIW.SI","USAW.SI","USJW.SI","TQQQ","TSYW.SI","BK4139","BLRX","PSQ","SCM","NQmain"],"gpt_icon":1},{"id":"2504905461","title":"BioLineRx Changes Ratio of ADSs to Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2504905461","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504905461?lang=en_us&edition=fundamental","pubTime":"2025-01-18 02:30","pubTimestamp":1737138612,"startTime":"0","endTime":"0","summary":"BioLineRx  will change the number of ordinary shares represented by American depositary shares to 600 shares per ADS from 15.The change in the exchange ratio will have the same effect as a 1-for-40 reverse stock split of the ADSs, lowering the number of outstanding ADSs to 3.56 million from 142.3 million, the company said Friday in a statement.The new ratio will take effect before the start of trading on the Nasdaq on Thursday.Price: 0.10, Change: -0.02, Percent Change: -17.80","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLRX","BK4139"],"gpt_icon":0},{"id":"2504997611","title":"S&P 500 Gains 1%; Fastenal Posts Downbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2504997611","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504997611?lang=en_us&edition=fundamental","pubTime":"2025-01-18 01:01","pubTimestamp":1737133277,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"a39edd96196a516577c3dca2fb60dbf4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/01/43062489/sp-500-gains-1-fastenal-posts-downbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUKK","FAST","BLRX","SCPX","JBHT",".SPX","VS","SPY","QRVO","VOO"],"gpt_icon":1},{"id":"2504715493","title":"BioLineRx changes ratio of ADRs to ordinary shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2504715493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504715493?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:05","pubTimestamp":1737115543,"startTime":"0","endTime":"0","summary":"BioLineRx (BLRX) announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-changes-ratio-of-adrs-to-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-changes-ratio-of-adrs-to-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2504122151","title":"BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2504122151","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504122151?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:00","pubTimestamp":1737115200,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-40 reverse stock split of the ADSs, reducing the number of outstanding ADSs from 142,340,133 to 3,558,503 ADSs. The ADSs will continue to trade on the Nasdaq Capital Market. BioLineRx's ordinary shares, which are not affected by the change, will continue to trade on the Tel Aviv Stock Exchange.Holders of BioLineRx's ordinary shares, which are traded on the Tel Aviv Stock Exchange , are unaffected by the new exchange ratio for ADSs. The Company's total outstanding share capital at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-announces-change-ratio-american-120000567.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biolinerx-announces-change-ratio-american-120000567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ",".IXIC","TSYW.SI","USAW.SI","QLD","USJW.SI","BK4117","BK4107","PSQ","QID","SQQQ","BK4139","NVIW.SI","NQmain","BLRX","AFG","MNQmain"],"gpt_icon":1},{"id":"2501425856","title":"BioLineRx Announces $10 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2501425856","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501425856?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:55","pubTimestamp":1736171700,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000of the Company's American Depositary Shares   and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS  and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.20 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date. Each ADS represents fifteen  ordinary shares, par value NIS 0.10 per share, of BioLineRx. The closing of the offering is expected to occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.BioLineRx Ltd.  is a biopharmaceutical company pursuing life-changing therapies in oncology and rare d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biolinerx-announces-10-million-registered-135500159.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biolinerx-announces-10-million-registered-135500159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BLRX","BK4139"],"gpt_icon":0},{"id":"2490533013","title":"Press Release: Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2490533013","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490533013?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:30","pubTimestamp":1733837400,"startTime":"0","endTime":"0","summary":"Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutations. Ilan Hadar, Chairman and CEO of Silexion, commented: \"We are thrilled to welcome Prof. Peled to our Board of Directors. His unparalleled expertise in cancer biology, stem cell mobilization, and therapeutic development will be invaluable as Silexion continues to advance its pipeline of RNAi-based therapies for difficult-to-treat cancers. Prof. Peled's track record in translating innovative science into impactful clinical outcomes aligns perfectly with our mission to address unmet needs in oncology.\". Prof. Peled serves as the Director of the Gene Therapy Institute at Hadassah Medical Center in Jerusalem, where his research focuses on cytokine roles in hematopoietic stem cell biology, inflammation, and cancer. Over his 28-year career, he has l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","BLRX","BK4585","03160","QID","BK4588","BK4555","SLXN","NQmain","BK4099","TM","SQQQ",".IXIC","MNQmain","PSQ","TQQQ","BK4139","LENZ"],"gpt_icon":1},{"id":"2488971924","title":"BLRX: Ayrmid Assumes Commercialization Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2488971924","media":"Zacks Small Cap Research","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488971924?lang=en_us&edition=fundamental","pubTime":"2024-12-04 00:11","pubTimestamp":1733242260,"startTime":"0","endTime":"0","summary":"A few days prior to its third quarter earnings report, BioLineRx Ltd.  announced a commercialization agreement with Ayrmid Ltd. and its subsidiary Gamida Cell Ltd. BioLineRx will grant Ayrmid rights to commercialize Aphexda  across all indications except in solid tumors and in all territories except Asia. The arrangement will provide a $10 million upfront payment to BioLineRx, royalties ranging from 18% to 23% and the potential for $87 million in commercial milestones. After a transition period, BioLineRx’ expenses are expected to decline by about 70% as the company reverts to a research and development firm.The announcement of the arrangement with Ayrmid was followed by the third quarter earnings report where total revenues reached $4.9 million and net loss was  million. Aphexda revenues were down sequentially to $1.7 million and lower than expected expenses across the board, especially sales and marketing led to the less severe-than-expected loss which was about 60% of what we had fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blrx-ayrmid-assumes-commercialization-efforts-161100452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","LU1291159041.SGD","IE00B3PB1722.GBP","LU0731783048.USD","LU1280957306.USD","ASH","IE00B64PRP62.GBP","BK4135","BK4534","LU2430703178.SGD","LU0772969993.USD","IE00BGHQF748.EUR","LU0648001328.SGD","LU1064131342.USD","LU2505996681.GBP","LU1988902786.USD","IE00BVYPNW00.USD","LU0742537680.HKD","LU1481011911.USD","IE00BDGV0183.EUR","BK4581","LU1989771016.USD","BLRX","IE00B42XCP33.USD","LU2430703251.USD","LU2430703095.HKD","BK4535","LU2463526074.USD","BK4139","BK4109","LU1599440770.SGD","BK4567","LU0731783394.SGD","BK4504","LU0980610538.SGD","LU0320765489.SGD","BK4585","BLK","IE00BGHQF631.EUR","LU1074936037.SGD","IE00B3QW5Z07.USD","IE00BVYPNV92.GBP","LU1670628061.USD","LU1481011671.HKD","LU0208291251.USD","LU1201861249.SGD","BK4588","LU0130102774.USD","LU0070302665.USD","LU2264538146.SGD"],"gpt_icon":1},{"id":"2486884156","title":"JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486884156?lang=en_us&edition=fundamental","pubTime":"2024-11-27 01:45","pubTimestamp":1732643109,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report) today. The company’s shares open...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLRX"],"gpt_icon":0},{"id":"2486002772","title":"BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts","url":"https://stock-news.laohu8.com/highlight/detail?id=2486002772","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486002772?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:00","pubTimestamp":1732633235,"startTime":"0","endTime":"0","summary":"Total Revenue: $4.9 million for Q3 2024, compared to no revenue in Q3 2023.Cost of Revenue: $0.8 million for Q3 2024, with no cost recorded in Q3 2023.Research and Development Expenses: $2.6 million for Q3 2024, down from $2.7 million in Q3 2023.Sales and Marketing Expenses: $5.5 million for Q3 2024, down from $8.1 million in Q3 2023.General and Administrative Expenses: $1.4 million for Q3 2024, slightly down from $1.5 million in Q3 2023.Net Loss: $5.8 million for Q3 2024, compared to $16 million in Q3 2023.Cash, Cash Equivalents, and Short-term Bank Deposits: $29.2 million as of September 30, 2024.Market Share of APHEXDA: Achieved 10% market share of total CXCR4 inhibitor usage in the US by end of Q3 2024.GuruFocus has detected 5 Warning Signs with BLRX.BioLine Rx Ltd  executed a significant licensing agreement with Ayrmid Ltd., providing a $10 million upfront payment and potential commercial milestones of $87 million.APHEXDA, BioLine Rx Ltd 's stem cell mobilization agent, achieved a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/N0d66K5qtIENnAyTSH3qgg--~B/aD0yMjt3PTIxNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/d79d11a91f6f8286cb526f81c4e041bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/N0d66K5qtIENnAyTSH3qgg--~B/aD0yMjt3PTIxNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/d79d11a91f6f8286cb526f81c4e041bd"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioline-rx-ltd-blrx-q3-150035812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BLRX"],"gpt_icon":0},{"id":"2486309120","title":"BioLine RX Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486309120","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486309120?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:23","pubTimestamp":1732555380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2024 12:23 ET (17:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2486672030","title":"BioLineRx price target lowered to $9 from $21 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2486672030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486672030?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:00","pubTimestamp":1732554007,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on BioLineRx (BLRX) to $9 from $21 and keeps a Buy rating on the shares after the company announced...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-price-target-lowered-to-9-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-price-target-lowered-to-9-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2486085141","title":"BioLineRx Secures Key Deals to Boost Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486085141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486085141?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:31","pubTimestamp":1732537904,"startTime":"0","endTime":"0","summary":"Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd has entered a strategic license agreement with Ayrmid Ltd. for its APHEXD...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biolinerx-secures-key-deals-to-boost-shareholder-value?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biolinerx-secures-key-deals-to-boost-shareholder-value?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"gpt_icon":0},{"id":"2486853083","title":"BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M","url":"https://stock-news.laohu8.com/highlight/detail?id=2486853083","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486853083?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:04","pubTimestamp":1732536257,"startTime":"0","endTime":"0","summary":"BioLineRx press release : Q3 GAAP EPS of $0.00  beats by $0.07. Revenue of $4.94M  misses by $0.35M. As of September 30, 2024, the company had cash, cash equivalents, and short-term bank deposits of $29.2 million. Following the out-license to Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4329101-biolinerx-gaap-eps-of-000-beats-by-007-revenue-of-494m-misses-by-035m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BLRX"],"gpt_icon":0},{"id":"2486088608","title":"BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2486088608","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486088608?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:02","pubTimestamp":1732536157,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.05) by 98 percent.  The company reported quarterly sales of $4.94 million which missed the analyst","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42160146/bioline-rx-q3-2024-gaap-eps-0-00-beats-0-05-estimate-sales-4-94m-miss-5-29m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"gpt_icon":0},{"id":"2486608861","title":"Press Release: BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486608861","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486608861?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:00","pubTimestamp":1732536000,"startTime":"0","endTime":"0","summary":"BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value. - Executed license agreement with Ayrmid Ltd. for APHEXDA  for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales -. - Entered into agreement to reduce and restructure long-term debt by $16.5 million -. - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA  commercial program to Ayrmid -. - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology -. \"Looking forward, our streamlined and nimble company has a new financial foundation supported by sales royalties and potential milestone payments, which will allow our experienced team to develop important new therapies in rare disease and oncology that address areas with high unmet need. We will also focus on advancing our motixafortide PDAC program ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4139","SCD","BLRX","R","BK4109","ASH","BK4022","BK4232"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biolinerx.com","stockEarnings":[{"period":"1week","weight":0.1141},{"period":"1month","weight":-0.1133},{"period":"3month","weight":-0.805},{"period":"6month","weight":-0.8744},{"period":"1year","weight":-0.9161},{"period":"ytd","weight":-0.5666}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.068634},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036883},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.095051},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.047194},{"month":5,"riseRate":0.538462,"avgChangeRate":0.061857},{"month":6,"riseRate":0.384615,"avgChangeRate":-0.023898},{"month":7,"riseRate":0.538462,"avgChangeRate":0.03754},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.055743},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.016762},{"month":10,"riseRate":0.357143,"avgChangeRate":-0.013928},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.057325},{"month":12,"riseRate":0.357143,"avgChangeRate":-0.060525}],"exchange":"NASDAQ","name":"BioLine Rx","nameEN":"BioLine Rx"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioLine Rx,BLRX,BioLine Rx股票,BioLine Rx股票老虎,BioLine Rx股票老虎国际,BioLine Rx行情,BioLine Rx股票行情,BioLine Rx股价,BioLine Rx股市,BioLine Rx股票价格,BioLine Rx股票交易,BioLine Rx股票购买,BioLine Rx股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction